Search This Blog

Saturday, May 30, 2020

Pew: Dems Represent 41 Of 44 Districts With Highest COVID-19 Death Tolls

by Sharyl Attkisson,
Pew Research Center is out with an analysis of coronavirus deaths. It shows they are overwhelmingly concentrated in Congressional districts represented by Democrats.
Democrats represent 41 of 44 districts with the highest number of Covid-19 deaths.

This lopsided distribution could help explain a partisan divide in the views regarding whether a national shutdown was the right move, and whether it’s time to end it.

From Pew:
The coronavirus outbreak has taken the lives of nearly 100,000 Americans. Yet since the start of the outbreak, the death toll has been concentrated in a just a few places – mostly large metropolitan areas, especially the New York City area.
The places hit hardest by the coronavirus outbreak – which have relatively large shares of ethnic and racial minorities and residents living in densely populated urban and suburban areas – are almost all represented by congressional Democrats.
A new Pew Research Center analysis of data on official reports of COVID-19 deaths, collected by the John Hopkins University Center for Systems Science and Engineering, finds that, as of last week, nearly a quarter of all the deaths in the United States attributed to the coronavirus have been in just 12 congressional districts – all located in New York City and represented by Democrats in Congress. Of the more than 92,000 Americans who had died of COVID-19 as of May 20 (the date that the data in this analysis was collected), nearly 75,000 were in Democratic congressional districts.
Of the 44 hardest-hit congressional districts – the top 10% in terms of deaths – 41 are represented by Democrats, while three are represented by Republicans. These include the New York-area districts, as well as those in the Boston, Detroit and New Orleans metropolitan areas. The average death toll in each of these hardest-hit districts was 1,122 as of May 20.
The next 100 hardest-hit districts, which represent the remainder of the top third of districts, with an average of 270 deaths, also are disproportionately represented by Democrats: 75 are represented by Democrats, 25 by Republicans.
About two-thirds (68%) of the 44 least affected districts – the bottom 10%, with an average 13 deaths in each district – are represented by Republicans in Congress.
Note: Pew finds there are differences in death rates in terms of race but not poverty level.
Read more here:  Coronavirus death toll is heavily concentrated in Democratic congressional districts
https://www.zerohedge.com/health/pew-democrats-represent-41-44-districts-highest-covid-19-death-tolls

ARYA Sciences Acquisition readies IPO

ARYA Sciences Acquisition Corp II (ARYBU) has filed a preliminary prospectus for $125M IPO via the sale of 12.5M units at $10, each consisting of one Class A ordinary share and 1/3 of a redeemable warrant.
The New York City-based and Cayman Island-domiciled blank check company aims to enter into a merger, asset acquisition, share purchase or some other combination with one or more, presently unidentified, businesses.
https://seekingalpha.com/news/3578829-arya-sciences-acquisition-readies-ipo

Bulgaria pins hopes on TB vaccine against coronavirus

In the worldwide battle against COVID-19, scientists are investigating whether a century-old tuberculosis vaccine might offer some additional protection against the novel coronavirus.
And Bulgaria—one of the world’s leading manufacturers of the —is holding out hope of new markets for the many millions of doses it produces each year.
Bacillus Calmette-Guerin, or BCG, was developed by two French researchers, Albert Calmette and Camille Guerin, in 1921 as a vaccine against tuberculosis, a that, according to the World Health Organization, is the world’s top infectious killer and the cause of 1.5 million deaths globally every year.
In the fevered search for a treatment against COVID-19, clinical trials are under way—in Australia, South Africa, Europe and the United States—to examine a hypothesis that BCG might provide a complementary shield against the novel coronavirus.
The WHO, for its part, said last month that there is no evidence that BCG protects people against infection with COVID-19.
Nevertheless, Bulgarian scientists suggest that the Balkan country’s high rate of BCG vaccination—as well as an early lockdown—helped it to escape the worst of the pandemic.
“BCG generates a powerful immune stimulation. And while we are waiting for a specific treatment or vaccine against the novel coronavirus, we must put our bets on immunity,” immunology professor Bogdan Petrunov told BNT public television.
Neonatologist Valentina Gerginova said that those who have had the vaccine experience “milder forms of other bacterial and viral infections” and that it could therefore also benefit those who are exposed to the novel .
Gerginova has administered BCG shots to newborn babies for more than 30 years at a private Sofia hospital.
While many countries now carry out only targeted BCG vaccination campaigns, Bulgaria insists on the mandatory vaccination of all newborn babies.
Bulgaria is also a major producer of the vaccine, exporting it to 140 countries. Its state-owned company Bul Bio is one of 22 pharmaceuticals firms worldwide that manufactures it, and only one of three in the European Union.
Bulgaria is also one of just four suppliers to the WHO—alongside India, Japan and Denmark—for the United Nations’ anti-tuberculosis campaigns in Africa and Asia.
‘Beneficial effects’
“We have known for many years that the BCG has some more general ,” Camille Locht, head of research at the National Institute of Health and Medical Research (Inserm) in the northern French city of Lille, told AFP.
The government hopes that Bulgaria, the EU’s poorest country, could benefit from its leading position as a major producer of BCG.
On a recent visit to Sofia-based Bul Bio, Prime Minister Boyko Borisov pledged additional funding of 10.4 million leva (5.2 million euros, $5.8 million) for a new production line that would double the company’s annual production to more than four million vials, the equivalent of 40 million shots.
“Due to the slim profit margins and the complex production process, there is real pressure on the supply of the vaccine on an international scale,” Bul Bio chief executive Rumen Kofinov told AFP.
Bulgaria’s expertise with BCG goes back a long way.
Among several different versions of the vaccine that were developed, one was tested in Bulgaria as far back as 1926. And large-scale production of BCG began in 1949 in a state laboratory that was Bul Bio’s predecessor.
In 1951, the country made the BCG vaccination obligatory for newborn babies, reducing to just one-tenth the number of tuberculosis cases in 30 years.
“We are the most BCG-ed country in the world,” with four obligatory shots administered before adulthood, the chief of Bulgaria’s National Centre for Infectious and Parasitic Diseases, Todor Kantardzhiev, said in a recent interview.
Despite this—and the fact that some other European states have never implemented mass BCG vaccination—tuberculosis infection rates are still twice as high in Bulgaria than the European average because of persistent poverty in some parts of the country.
https://medicalxpress.com/news/2020-05-bulgaria-pins-tb-vaccine-coronavirus.html

Ultraviolet light has bright future in fight against COVID-19

A particular type of ultraviolet light known as far-UVC could be safely used for air disinfection in public places without harming people, according to new research carried out jointly at the University of St Andrews and Ninewells Hospital in Dundee.
This research is very timely as the world looks for new ways to disinfect rooms and help eliminate the Covid-19 coronavirus.
In the research, accepted for publication in the journal Photodermatology, Photoimmunology and Photomedicine, the St Andrews-Ninewells team used to study the impact of far-UVC lamps on and have shown the wavelengths that do not cause the kind of problems typically associated with ultraviolet light.
There are three types of – UVA, UVB and UVC – all of which have the potential to damage human .
Isla Barnard, a medical physics PhD student at St Andrews, said: “The Earth’s atmosphere protects us by absorbing all the UVC from the Sun, and we must be very careful to protect ourselves from some existing UVC disinfectant lamps which are known to cause .
“Using our computer model, we have shown that longer UVC wavelengths can damage the skin whilst wavelengths shorter than 230nm had much more limited penetration in the skin.”
UVC light from special germicidal lamps with wavelengths in the range 200nm to 280nm kills germs such as bacteria and viruses and has been used as a means of disinfecting hospital wards and operating theatres for decades. However, the wards must be empty of people because the germicidal lamps operate mainly at a wavelength of 254nm that can penetrate the eyes and skin, causing inflammation and pain.
Far-UVC lamps that emit at wavelengths around 222nm may be safer because proteins in the skin efficiently absorb this light and provide a natural protective barrier.
The computer codes at the heart of this work were originally developed by St Andrews astrophysicist Dr Kenny Wood and have been adapted to help treat patients.
Dr Wood said: “Over the last decade we have built an interdisciplinary collaboration with photobiologists at Ninewells. Together, we have a strong track record in using computer simulations for testing optical and ultraviolet lamps and optimising light-based therapies for skin cancer and other diseases.”
Dr Ewan Eadie of the Photobiology Unit at Ninewells Hospital said: “Our new simulations provide further support for existing laboratory research showing that the upper layers of the skin provide a natural protection against shorter-wavelength-UVC.
“Lamps that are engineered to filter out ultraviolet wavelengths longer than 230nm are safer than existing germicidal lamps. We now require real-life in-person studies to support our computer simulations and the laboratory evidence.”
Lamps that emit at the shorter 222nm are now being investigated worldwide as a means to help eliminate the virus responsible for the current Covid-19 global pandemic.

Explore further
Follow the latest news on the coronavirus (COVID-19) outbreak

More information: Isla Rose Mary Barnard et al. Further evidence that far‐UVC for disinfection is unlikely to cause erythema or pre‐mutagenic DNA lesions in skin, Photodermatology, Photoimmunology & Photomedicine (2020). DOI: 10.1111/phpp.12580

When COVID-19 meets flu season

As if the COVID-19 pandemic isn’t scary enough, the flu season is not far away. How severe will the flu season be as it converges with the COVID-19 outbreak? What can we do to prepare?
Dr. Benjamin Singer, a Northwestern Medicine pulmonologist who treats COVID-19 patients in the , outlines the best defense against influenza, which also may protect against coronavirus.
In an editorial that will be published May 29 in the journal Science Advances, Singer, an assistant professor of pulmonary and critical care and biochemistry and molecular genetics at Northwestern University Feinberg School of Medicine, examines the epidemiology and biology of SARS-CoV-2 and influenza to help inform preparation strategies for the upcoming flu season.
He outlines the following four factors that could determine the severity of the upcoming :
1. Transmission: Social distancing policies designed to limit the spread of COVID-19 are also effective against the flu. If COVID-19 cases begin to spike in the fall of 2020, re-tightening social distancing measures could help mitigate early spread of the flu to flatten the curves for both viruses.
2. Vaccination: As we await vaccine trials for COVID-19, we should plan to increase rates of vaccination against the flu, particularly among older adults who are more susceptible to both the flu and COVID-19.
3. Co-infection: We need widespread availability of rapid diagnostics for COVID-19 and other because co-infection with another respiratory pathogen, including the flu, occurred in more than 20% of COVID-19-positive patients who presented with a respiratory viral syndrome early in the pandemic.
4. Disparities: The COVID-19 pandemic has highlighted unconscionable disparities among African Americans, Latinx and Native Americans so we must galvanize public health efforts aimed to limit viral spread, increase vaccination rates, deploy rapid diagnostics and expand other health care services for vulnerable populations, including communities of color, the poor and .
The Centers for Disease Control and Prevention estimated that the 2019-2020 seasonal influenza epidemic resulted in tens of millions of cases and tens of thousands of deaths.
“Even in non-pandemic years, the flu and other causes of pneumonia represent the eighth-leading cause of death in the United States, and respiratory viruses are the most commonly identified pathogens among hospitalized patients with community-acquired pneumonia,” Singer said.

Explore further
Clinicians treating COVID-19 say don’t rush to try novel therapies

More information: “COVID-19 and the next influenza season,” Science Advances (2020). advances.sciencemag.org/lookup … .1126/sciadv.abd0086

Coronavirus hopes and fears center on ‘immunity’

Could exposure to the coronaviruses that cause the common cold help protect against COVID-19? Is herd immunity closer than previously thought?
As nations lift lockdowns and experts worry about a potential second peak in cases, our ability to ward off infection is one of the hottest topics of scientific debate.
Ever since it became apparent that children were less vulnerable to COVID-19 early in the pandemic, scientists have speculated that the regular spread of benign viruses in places like schools could have bolstered their to the latest coronavirus.
Now the idea of “cross immunity” among the broader population is gaining some ground.
In a recent post on Twitter, Francois Balloux of University College London noted an “intriguing” lack of an immediate resurgence in COVID-19 cases following the easing of lockdowns in several countries.
Among the possible explanations, he noted, were seasonality and enduring social distancing practices.
But he posited a “wilder” hypothesis as well—that a “proportion of the population might have pre-existing immunity to #SARSCoV2, potentially due to prior exposure to ‘common cold’ coronaviruses”.
Balloux said that might explain issues like cases where there is no transmission between spouses.
Earlier this month, an American study in the journal Cell suggested between 40 and 60 percent of the population could be immunized against COVID-19 without ever being exposed to it.
Researchers put this down to the action of protective cells, known as T lymphocytes, that had been activated by other coronaviruses responsible for colds.
But authors Alessandro Sette and Shane Crotty, of La Jolla Institute for Immunology, cautioned that the research did not suggest the epidemic was running out of steam.
“Clearly some individuals are more susceptible to the disease than others; after being infected some individuals have severe clinical symptoms and might even die, while others might show very little in terms of clinical symptoms,” they told AFP by email.
“Our study suggests that preexisting immunity might be one of the factors to be considered; but at this point is simply an hypothesis that needs to be addressed with further experiments.”
‘Jury out’
The World Health Organization has also expressed caution over the issue.
“There is certainly some evidence with regard to T cells, that if you have a previous coronavirus infection you may be able to mount a more rapid response to COVID-19,” said the WHO’s Michael Ryan at a press conference this week.
“But there’s no empirical evidence that previous coronavirus infections protect you from infection with COVID-19. The jury is still very much out on that,” he added.
However, Ryan said it was an encouraging sign for the development of vaccines.
“It gives us hope that we are getting the kinds of immune responses that may be helpful to long-term protection,” he said.
New waves?
Another uncertainty is whether everyone is equally vulnerable to catching COVID-19.
A growing number of scientists think maybe not, raising questions over assumptions for what is known as herd immunity.
Gabriela Gomes, a researcher at the Liverpool School of Tropical Medicine, told AFP that it was wrong to assume that one person is as susceptible to the virus as another, or as exposed.
“We know little about the factors which underlie this individual variation. It could be cross-immunity with other coronaviruses, but it could also be other microbes, genetics, age, behaviour, and most likely a combination of many factors,” she said.
In theory this could explain why early estimates of the proportion of individuals who have been infected by the new coronavirus have been lower than expected—at around 5 to 10 percent of the in several countries.
It could also mean a lower threshold for herd immunity—when a sufficient part of the population has caught the virus, starving it of new hosts to spread to and thereby stopping the epidemic.
This threshold, commonly accepted as around 60 to 70 percent of the population infected, is what Sweden hoped to achieve by deciding against a strict lockdown.
But Gomes said that mathematical models on herd immunity often “ignore individual variation”.
According to a study she co-authored, which has not yet been peer reviewed, the threshold might be reached when just 10 to 20 percent of the population has been infected.
Gomes said her research, which simulated the lifting of social distancing measures over the next six to 12 months, suggested that even if countries that had been severely affected are “closer to “, they would still see more localised outbreaks.
There could also be “what may seem like a second wave in those countries that have been less affected so far”.
At the Pitie-Salpetriere hospital in Paris, professor of emergency medicine Yonathan Freund has noticed a sharp drop in the number of infections among doctors compared with the start of the epidemic.
“This is pure speculation but it could mean that people have natural or acquired immunity,” he told AFP.
It is giving him confidence.
With infections staying low three weeks after France lifted its strict lockdown measures, he thinks that could mean “the second wave is not coming and probably will not happen” in the country.
https://medicalxpress.com/news/2020-05-coronavirus-centre-immunity.html

ASCO 2020: Some Presentations and Topics at this Year’s Virtual Con

The American Society of Clinical Oncology (ASCO) 2020, one of the biggest cancer conferences of each year, is, of course, going to be virtual this year because of the COVID-19 pandemic. The dates for the meeting are May 29-31 with the opening session at 9:30 AM EST followed in the morning with highlights of various cancer indications, such as breast cancer, and head and neck cancer at 10:30, central nervous system tumors and gastrointestinal cancers at 11:00 and gynecologic and hematologic malignancies at 11:30. The afternoon is marked by various symposia, such as “Harnessing Immunotherapy with Novel Approaches Beyond Checkpoint Inhibitors,” and “Redefining Cancer of Unknown Primary: Is Genomics the Answer?”
Numerous biopharmaceutical companies and researchers are presenting research and clinical trial results, and many have been announcing their plans for several weeks. Examples include but are not limited to:

Genentech, a Roche company, announced positive results from the Phase II CITYSCAPE clinical trial in PD-L1-positive metastatic non-small cell lung cancer (NSCLC). The study evaluated a new checkpoint inhibitor tiragolumab and its checkpoint inhibitor Tecentriq (atezolizumab) compared to Tecentriq alone.
Tiragolumab is a novel immunotherapy that binds to TIGIT, an immune checkpoint protein found on immune cells. Tecentriq is a PD-L1 checkpoint inhibitor. Both TIGIT and PD-L1 are involved in immune suppression. Blocking both pathways has the potential for improving anti-tumor activity.
The company plans to present the full data at an oral abstract session.
Merck announced positive data from the Phase III KEYNOTE-355 trial looking at Keytruda in combination with chemotherapy as first-line treatment for metastatic triple-negative breast cancer (mTNBC). It is presenting the data at an oral abstract session. In the trial, patients whose tumors expressed PD-L1 with a Combined Positive Score (CPS) greater than or equal to 10, Keytruda with chemotherapy showed a statistically significant and clinically meaningful improvement in progression-free survival (PFS). The drug combination decreased the risk of disease progression or death by 35%, improving PFS to a median of 9.7 months compared to 5.6 months for patients receiving only chemotherapy.
Bristol Myers Squibb is presenting numerous data including new data from two clinical trials of Opdivo plus Yervoy-based combinations in non-small cell lung cancer (NSCLC) and updated results from the KarMMa trial of ide-cel for multiple myeloma being developed with bluebird bio.
For Part 1 of the Phase III CheckMate -227 clinical trial, the company announced three-year follow-up data showing that Opdivo (nivolumab) plus Yervoy (ipilimumab) gave sustained improvements in overall survival (OS) as well as additional efficacy measures as a first-line treatments for metastatic NSCLC. The median follow-up was more than three years—43.1 months—and the combination showed a survival benefit compared to chemotherapy in patients expressing PD-L1 greater than 1%. The three-year OS rates in this population was 33% for the combination compared to 22% for chemotherapy alone.
In the Phase III CheckMate -9LA trial, the company presented first results showing a statistically significant and clinically meaningful survival benefit with Opdivo plus Yervoy, given concomitantly with two cycles of chemotherapy for first-line metastatic NSCLC. The trial met both its primary and key secondary endpoints, showing superior OS, progression-free survival (PFS) and overall response rate (ORR) for the dual immunotherapy plus chemotherapy compared to chemotherapy alone.
For the Phase II KarMMa trial, the two companies presented updated results in patients with relapsed and refractory multiple myeloma (r/r MM). In the trial, 128 patients with heavily pretreated r/r MM who were exposed to at least three previous therapies and were refractory to their last regimen were treated with ide-cel. The overall response rate (ORR) was 73% across all dose levels, including 33% who had a complete response (CR) or stringent CR (sCR). Median duration of response (DoR) was 10.7 months, with 19.0-month median DoR for patients who had a CR or sCR.
Researchers from U.S. Oncology Research and McKesson are planning to describe results from more than 70 studies, including six oral sessions on immunotherapy and specific cancer indications such as prostate, ovarian, breast and others.
“The uncertainties of cancer care and research during today’s pandemic are having a profound effect on patients, oncologists and researchers,” stated Robert L. Coleman, chief scientific officer, US Oncology Research. “Our team of community-based research investigators are committed to advancing research, even in challenging times, to examine new and improved therapies, diagnostics and other aspects of clinical cancer care, as cancer will not wait for us.”
Nucleix, a liquid biopsy company out of San Diego and Rehovot, Israel, is presenting data from research using a blood-based methylation assay for cancer detection. The six-marker assay is the initial component of the company’s screening tests in early cancers and leverages existing, low-cost PCR tech. The presentation is by Lasika Seneviratne, SCORA/LA Cancer Network titled, “Discovery of a core-panel of markers for a blood-assay for cancer detection utilizing cfDNA methylation changes.”
Bayer is presenting data from the pre-specified final overall survival (OS) analysis of its study of Nubeqa (darolutamide) plus androgen deprivation therapy (ADT) in non-metastatic castration-resistant prostate cancer (nmCRPC). The data shows significantly improved OS compared to ADT alone.
AstraZeneca is presenting quite a bit of research, including an abstract on AZD9833 in preclinical models of breast cancer (the experimental drug is currently in an ongoing Phase I trial in pre- and post-menopausal women); an abstract on a Phase III trial of capivasertib and paclitaxel in first-line treatment of metastatic triple-negative breast cancer; and an abstract on the Phase II trial of savolitinib in patients with pulmonary sarcomatoid carcinoma (PSC) and other types of non-small cell lung cancer (NSCLC) that harbor MET exon 14 skipping mutations.
As usual, there will be a wealth of clinical and preclinical research presented. Although the video streaming and virtual aspects of the conference will likely hinder more casual conversation, a popular topic will probably be the effect of the pandemic on clinical trials and research as well. Stay tuned for interesting stories.
https://www.biospace.com/article/asco-2020-preview-a-peek-at-some-of-presentations-and-topics-at-this-year-s-virtual-con/